Axitinib Therapy Management Study

Retrospective Analysis of Axitinib Treatment Optimization and Management of Selected Immune Related Adverse Events of Checkpoints Inhibitors

The objectives of the study is to describe axitinib therapy management through use of the data to be generated by ConcertAI

not mandatory

Inclusion Criteria:

• Confirmed diagnosis of aRCC (Stage III, Stage IV (M0) or Stage IV (M1)) at any point
• Age 18 years or older at the time of aRCC diagnosis
• Received a qualifying IO-containing combination (nivolumab and ipilimumab, axitinib and pembrolizumab, or axitinib and avelumab) in the first regimen after aRCC diagnosis or axitinib monotherapy in any line

Exclusion Criteria:

• none